Roche raises Illumina bid to $6.7 billion
April 2, 2012Sales and Marketing
Roche has increased its takeover bid for Illumina, with the offer now valuing the company at $6.7 billion.The firm makes …
Teva sells Canadian plant to CMO
March 30, 2012Manufacturing and Production CMO, Halo Pharmaceutical, Teva, manufacturing
Teva has said it plans to sell a manufacturing facility in Quebec, Canada, to US contract manufacturing organisation Halo Pharmaceutical. …
Amylin dismisses BMS acquisition deal
March 30, 2012Manufacturing and Production, Sales and Marketing Amylin, BMS, Bydureon, diabetes, lilly
Amylin Pharmaceuticals has rebuffed a $3.5 billion unsolicited takeover bid from Bristol-Myers Squibb, according to reports. Shares in Amylin rose …
Merck appoints new chief ethics and compliance officer
March 30, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Bowles, Holston, MSD, Merck
Merck has announced the appointment of Michael Holston as chief ethics and compliance officer. Holston is to succeed Richard Bowles, …
NICE recommends Xgeva for bone metastasis
March 29, 2012Sales and Marketing Amgen, NICE, Xgeva, Zytiga, denosumab, prostate cancer
NICE has issued draft guidance recommending Amgen’s Xgeva (denosumab) for certain groups of cancer patients whose disease has spread to …
Approval for Affymax and Takeda’s anaemia treatment
March 29, 2012Sales and Marketing Affymax, Amgen, ESA, Epogen, Takeda, omontys
The first rival treatment to Amgen’s portfolio of anaemia drugs has been approved in the US.Omontys (peginesatide) has been developed …
Inovio appoints ex-Merck vaccines president Dr Adel Mahmoud
March 29, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Inovio, Merck, vaccines
Inovio Pharmaceuticals has announced that Dr Adel Mahmoud has been appointed to its Board of Directors. Mahmoud, a global infectious …
Prostate cancer drug extends life after chemotherapy
March 29, 2012Research and Development, Sales and Marketing Astellas, Medivation, Zytiga, prostate cancer
Prostate cancer treatment MDV3100 has been shown to extend life by nearly five months in men with advanced disease who …
Janssen to remove its Psoriasis 360 Facebook page
March 28, 2012Medical Communications Facebook, Janssen, PM Soc, Psoriasis 360
Janssen has decided to take down its award-winning Psoriasis 360 page on Facebook, citing an increasing amount of troublesome comments. …
Omnicom Group chooses CAHG as its lead healthcare agency
March 28, 2012Medical Communications CAHG. TBWA, Omnicom, WorldHealth
The Omnicom Group has chosen its healthcare comms agency CAHG to form a strategic alliance with TBWA\WorldHealth as the company’s …
GSK settles cancer patent dispute
March 28, 2012Research and Development, Sales and Marketing GSK, Genmab, Roche, ofatumumab, patents
GlaxoSmithKline has settled a long-running patent dispute over its cancer treatment ofatumumab. The US patents, which relate to recombinant antibody …
NHS reforms become law
March 28, 2012Sales and Marketing CCGs, Commissioning Board, Lansley, NHS, PCTs, QIPP, reforms
After 18 months of political wrangling and mass opposition, the government’s reform of the NHS in England has been passed …
Sanofi sets up cholesterol drug showdown with Amgen
March 27, 2012Research and Development, Sales and Marketing Amgen, BMS, LDL, Lipitor, Merck, Regeneron, Sanofi
Sanofi and Amgen have posted results for their new injectable cholesterol drugs within 24 hours of each other. Both drugs …
Pharma manufacturing news in brief
March 27, 2012Manufacturing and Production Apotex, Ei Inc, Oxford Pharmascience and Bend Research, PharmaForm
Apotex sues FDA, Ei expands its production facilities in North Carolina, plus new developments at PharmaForm, Oxford Pharmascience and Bend …
Merck KGaA manufacturing under scrutiny by FDA
March 27, 2012Manufacturing and Production FDA, Merck KGaA, Rebif, Violations, manufacturing
The US Food and Drug Administration has asked Merck KGaA to undertake a ‘comprehensive and global assessment’ of its manufacturing …
Risk register spells out NHS reform risks
March 27, 2012Sales and Marketing NHS reforms, commissioning, health bill, risk register
A leaked document that assesses problems with the government’s reform of the NHS has been published by the Guardian. The …
Teva launches generic Seroquel in UK
March 27, 2012Sales and Marketing AZ, NHS, Quetiapine, Seroquel, Teva
Teva has launched a generic version of the antipsychotic Seroquel on the same day AstraZeneca loses patent protection on its …
FDA warns against phthalate use in medicines
March 27, 2012Manufacturing and Production FDA, SUPAC, manufacturing, phthalates
The Food and Drug Administration has warned pharma companies not to use two phthalates as excipients in both biological products and drugs, …
Contract research news in brief
March 27, 2012Research and Development AMRI, Cetero, Kforce, Particle Sciences and QED Clinical Services, inVentiv Health
Cetero files for bankruptcy after FDA admonishments, AMRI shutters Hungarian facility and inVentiv Health buys Kforce; also updates from Particle …
UK government launches new dementia programme
March 26, 2012Medical Communications, Sales and Marketing Alzheimer's, Cameron, UK, dementia
The government has signalled its intention to boost dementia funding and awareness with its new ‘challenge on dementia’ campaign. In …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
